Application of Simiaoyong'an Decoction in regulating miR-548j-5p / IL-17A signaling axis in the treatment of vasculitis
By discovering the mechanism of action of the signal axes of miR-548j-5p and IL-17A in TAO, SiMiaoyongan Decoction promotes miR-548j-5p expression to inhibit IL-17A, solving the difficulties in TAO diagnosis and treatment, and providing The new diagnostic and treatment methods have significant practical application value.
Patent Information
- Application Number
- CN202410047895.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-11
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-01-11
AI Technical Summary
Thromboocytic vasculitis (TAO) lacks sensitive and specific early diagnostic markers, which hinders timely and effective treatment of TAO patients, and its molecular biological mechanism is unclear.
Through research, it was found that miR-548j-5p was downregulated in TAO patients and could inhibit its expression by binding to the 3'UTR of IL-17A. SiMiaoyongan Decoction can promote the expression of miR-548j-5p, thereby inhibiting IL-17A , and then have a therapeutic effect on TAO.
It provides new targets and pathways, provides new methods for clinical diagnosis and treatment of TAO, has good practical application value, and has been developed for screening, Products and systems that assist in diagnosis, detection, monitoring or predicting TAO progress.
Smart Images

Figure CN117867101B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to the application of Simiao Yong'an Decoction in regulating the miR-548j-5p / IL-17A signaling axis in the treatment of vasculitis. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Thromboangiitis obliterans (TAO) is a chronic, progressive, segmental peripheral vascular disease that mainly affects the small and medium-sized arteries and veins in the upper and lower extremities of patients. It is common in young and middle-aged people aged 20 to 40, usually with a history of smoking, and is widely distributed in the Middle East, Far East, Southeast Asia, Eastern Europe, and South America. Clinical manifestations usually begin with ischemic symptoms caused by stenosis or occlusion of distal arterioles. Early typical symptoms mainly include intermittent claudication of the lower legs and resting pain at night. As the disease progresses, ischemic ulcers, amputations, and even death occur at the extremities. Prospective studies have found that 34% of TAO patients will undergo amputation within 15 years of diagnosis, with an average age of death of 52 years. To date, the molecular biological mechanism of TAO remains unclear, and the lack of sensitive and specific early diagnostic markers has hindered the timely and effective treatment of TAO patients.
[0004] Simiao Yong'an Decoction was first recorded in the Secret Biography of Hua Tuo, a divine doctor, in the Eastern Han Dynasty, and was later included in the New Compilation of Proven Prescriptions in the Qing Dynasty. It is a traditional Chinese medicine prescription composed of honeysuckle, Scrophularia, Angelica and Licorice in a ratio of 3:3:2:1. It is a commonly used prescription for the treatment of "gangrene" with damp-heat toxicity, and has the effects of clearing away heat and detoxification, promoting blood circulation and removing blood stasis, and dredge meridians and relieve pain. Modern studies have shown that Simiao Yong'an Decoction has pharmacological effects such as anti-inflammatory, lipid-lowering, and plaque stabilization in the treatment of peripheral vascular diseases. At the same time, clinical observations have shown that Simiao Yong'an Decoction has a good therapeutic effect in the treatment of TAO patients. Therefore, clarifying the mechanism of action of Simiao Yong'an Decoction on TAO patients will help provide direction for exploring biomarkers and targeted treatments for TAO. Summary of the invention
[0005] In view of the deficiencies in the prior art, the present invention provides the application of Simiao Yong'an Decoction in regulating the miR-548j-5p / IL-17A signal axis in the treatment of vasculitis. The present invention has found through research that the expression of IL-17A in peripheral blood mononuclear cells (PBMCs) of TAO patients is increased. At the same time, miRNA chip analysis found that miR-548j-5p is a downregulated miRNA in TAO patients. Further studies have found that miR-548j-5p can inhibit the expression of IL-17A by binding to its 3′UTR. On this basis, in vitro and in vivo animal experiments were conducted on the mechanism of action of Simiao Yong'an Decoction in the treatment of TAO. The results showed that Simiao Yong'an Decoction can promote the expression of miR-548j-5p, thereby inhibiting IL-17A, and then playing a therapeutic role in TAO rats. Based on the above research results, the present invention is completed.
[0006] Specifically, the present invention relates to the following technical solutions:
[0007] The first aspect of the present invention provides the use of a reagent for detecting miR-548j-5p and / or IL-17A in the preparation of a product for screening, (auxiliary) diagnosis, detection, monitoring or prediction of the progression of thromboangiitis obliterans.
[0008] A second aspect of the present invention provides a system for screening, (assisting) diagnosing, detecting, monitoring or predicting the progression of thromboangiitis obliterans, the system comprising:
[0009] An acquisition module is configured to: acquire the expression level of miR-548j-5p and / or IL-17A in a sample to be tested of a subject;
[0010] The evaluation module is configured to determine the disease condition of the subject according to the expression level of miR-548j-5p and / or IL-17A obtained by the acquisition module.
[0011] The third aspect of the present invention provides the use of a preparation containing Simiao Yong'an Decoction in at least one of the following:
[0012] (a1) promoting the expression of miR-548j-5p and / or eNOS in vascular endothelial cells or preparing a product that promotes the expression of miR-548j-5p and / or eNOS in endothelial cells;
[0013] (a2) inhibiting the expression of IL-17A, TF and / or vWF in vascular endothelial cells or preparing a product that inhibits the expression of IL-17A, TF and / or vWF in endothelial cells;
[0014] (a3) Drugs for the treatment of thromboangiitis obliterans.
[0015] Beneficial technical effects of one or more of the above technical solutions:
[0016] The above technical solution studied the role of miR-548j-5p and IL-17A in the occurrence of thromboangiitis obliterans and the targeted regulation mechanism of Simiao Yong'an Decoction from an epigenetic perspective, providing new targets and pathways for clinical diagnosis and treatment, and has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0018] Figure 1 The liquid chromatography-mass spectrometry of Simiao Yong'an Decoction in the embodiment of the present invention is shown in Figure 2; (A) Base peak chromatogram of LC-MS / MS analysis of Simiao Yong'an Decoction in negative ion mode. (B) Base peak chromatogram of LC-MS / MS analysis of Simiao Yong'an Decoction in positive ion mode. Vertical axis: Relative Abundenoe.
[0019] Figure 2 The expression of IL-17A mRNA and protein in the control group and TAO group in the present invention; (A) qRT-PCR analysis of IL-17A mRNA expression in PBMCs of TAO patient group (n=20) and control group (n=20). (B) ELISA analysis of IL-17A protein expression in serum of TAO patient group (n=20) and control group (n=20).
[0020] Figure 3 It is the differential miRNA screening in the embodiment of the present invention; specifically, it is a Venn diagram of differentially expressed miRNAs regulating IL-17A predicted by TargetScan database, miRDB and chip.
[0021] Figure 4 Figure 1 is the screening of differential miRNAs regulating IL-17A in the embodiment of the present invention; (A) back sample detection. (B) qRT-PCR analysis of miR-548j-5p in TAO patients and control group (n=20) Figure (C) is the correlation analysis of IL-17A mRNA and miR-548j-5p in PBMCs; (D) is the ROC curve analysis of the diagnostic value of miR-548j-5p for TAO. **p<0.01, compared with the normal group.
[0022] Figure 5The effect of regulating miR-548j-5p on IL-17A mRNA in the present invention; (AD) The expression levels of miR-548j-5p and IL-17A mRNA after transfection with NC, miR-548j-5p mimics, INC and miR-548j-5p inhibitor were detected by qRT-PCR. **p<0.01.
[0023] Figure 6 The effect of regulating miR-548j-5p on IL-17A protein in the embodiment of the present invention; the expression level of IL-17A protein after transfection of NC, miR-548j-5p mimics, INC and miR-548j-5p inhibitor was detected by ELISA. **p<0.01.
[0024] Figure 7 The effect of regulating miR-548j-5p on the expression of vascular-related proteins in the embodiment of the present invention; the protein expression levels of vWF, eNOS and TF after transfection of NC, miR-548j-5p mimics, INC and miR-548j-5p inhibitor were detected by Western blot. **p<0.01.
[0025] Figure 8 The targeted regulatory relationship between miR-548j-5p and IL-17A in the embodiment of the present invention; (A) shows that miR-548j-5p and IL-17A3'UTR have two potential binding sites and mutation sequences; (B) shows the effect of miR-548j-5p mimics on the luciferase activity of WT-pmirGLO-IL-17A and Mut-pmirGLO-IL-17A3'UTR verified by dual luciferase reporter gene experiment. *P<0.05, **P<0.01, WT represents wild type; MUT represents mutant.
[0026] Fig. 9 Figure 3 is the thrombosis situation of the control group, sham operation group and TAO rat model group in the embodiment of the present invention; (A, B) HE staining (magnification, ×100), scale bar = 100 μm and Doppler ultrasound from the control group, sham operation group and TAO group rats (n = 5).
[0027] Fig.10The expression of miR-548j-5p and IL-17A in the control group, sham operation group and TAO model group in the embodiment of the present invention; (A) qRT-PCR analysis of miR-548j-5p in PBMCs of the control group, sham operation group and TAO rat group, (n=5). (B) qRT-PCR analysis of IL-17A mRNA in PBMCs from the control group, sham operation group and TAO rat group, (n=5). (C) ELISA analysis of IL-17A protein expression in the serum of the control group, sham operation group and TAO rat group, (n=5). **p<0.01.
[0028] Fig.11 The expression of vascular function-related proteins in the control group, sham operation group and TAO model group in the present invention; Western blot analysis of vWF, eNOS and TF proteins in vascular tissues from the control group, sham operation group and TAO rat group (n=5). **p<0.01.
[0029] Fig.12 This is the effect of neutralizing IL-17A on thrombus in the embodiment of the present invention; Note: HE staining (magnification, ×100), scale bar = 100 μm was used to detect the control group, TAO+NS group (n=5), and neutralizing antibody group (n=5) to observe the changes in thrombus.
[0030] Fig.13 It is the signal pathway in which the active ingredients of Simiao Yong'an Decoction in the embodiment of the present invention act on TAO.
[0031] Fig.14 : The effect of SMYA on miR-548j-5p and IL-17A in HUVECs in the embodiment of the present invention; (A) After 24 hours of culture, the expression of miR-548j-5p in HUVECs was analyzed by qRT-PCR in the control group, low-dose SMYA group, medium-dose SMYA group, and high-dose SMYA group. (B) After 24 hours of culture, the expression of IL-17A mRNA in HUVECs was analyzed by qRT-PCR in the control group, low-dose SMYA group, medium-dose SMYA group, and high-dose SMYA group. (C) After 24 hours of culture, the expression of IL-17A protein in the cell supernatant was analyzed by ELISA in the control group, low-dose SMYA group, medium-dose SMYA group, and high-dose SMYA group. **p<0.01.
[0032] Fig.15The expression of vascular function-related proteins in HUVECs by SMYA in the present invention; 24 hours after culture, Western bolt analysis of the control group, low-dose SMYA, medium-dose SMYA, and high-dose SMYA groups, vWF, eNOS, and TF protein expression. **p<0.01.
[0033] Fig.16 The effect of miR-548j-5p on IL-17A in the SMYA treatment group in the embodiment of the present invention; (A) 24h after culture, qRT-PCR analysis of miR-548j-5p expression in the control group, high-dose SMYA group, high-dose SMYA+INC group, and high-dose SMYA+inhibitor group. (B) 24h after culture, qRT-PCR analysis of IL-17A mRNA expression levels in rats in the control group, high-dose SMYA, high-dose SMYA+INC, and high-dose SMYA+inhibitor groups. (C) 24h after culture, ELISA detection of IL-17A protein expression in the cell supernatant in the control group, high-dose SMYA, high-dose SMYA+INC group, and high-dose SMYA+inhibitor group.
[0034] Fig.17 This is the effect of miR-548j-5p on the expression of vascular-related proteins in the SMYA treatment group in the present invention; 24 hours after culture, Western blot analysis was used to detect the expression of vWF, eNOS and TF proteins in vascular tissues of the control group, high-dose SMYA group, high-dose SMYA+INC group, and high-dose SMYA+inhibitor group. **p<0.01.
[0035] Fig.18 The effect of SMYA on thrombus in TAO rats in the present invention; (A) The control group, low, medium and high (SMYA) groups, Doppler ultrasound analysis of rat blood vessels on the 7th day (n = 5). (B) The changes in thrombus size and volume of the control group, low, medium and high (SMYA) groups after intragastric administration for 7 days were observed (n = 5). **p < 0.01.
[0036] Fig.19The effect of SMYA on miR-548j-5p and IL-17A in TAO rats in the embodiment of the present invention; (A) qRT-PCR analysis of miR-548j-5p expression in rats of the control group, low-dose SMYA, medium-dose SMYA, and high-dose SMYA groups (n=5). (B) qRT-PCR analysis of IL-17A mRNA in rats from the control group, low-dose SMYA, medium-dose SMYA, and high-dose SMYA groups (n=5). (C) ELISA analysis of IL-17A protein in serum from the control group, low-dose SMYA, medium-dose SMYA, and high-dose SMYA groups (n=5), **p<0.01.
[0037] Fig. 20 This is the effect of SMYA on the expression of vascular function-related proteins in TAO rats in the example of the present invention; Western blot detected the expression of vWF, eNOS and TF proteins in vascular tissues of the control group, low-dose SMYA, medium-dose SMYA and high-dose SMYA groups, **p<0.01, (n=5).
[0038] Fig.21 This is the effect of reducing the expression of miR-548j-5p on thrombosis in rats in the embodiment of the present invention; HE staining of vascular tissue of the control group, high-dose Simiao Yong'an Decoction group, high-dose Simiao Yong'an Decoction + INC group, and high-dose Simiao Yong'an Decoction + inhibitor group (magnification × 100), scale bar = 100 μm, (n = 5).
[0039] Fig. 22 The effect of miR-548j-5p on IL-17A in the SMYA treatment group in the embodiment of the present invention; (A) qRT-PCR detected the expression of miR-548j-5p in the rats of the control group, high-dose SMYA, high-dose SMYA+INC, and high-dose SMYA+inhibitor groups (n=5). (B) qRT-PCR detected the expression of IL-17A mRNA in the rats of the control group, high-dose SMYA, high-dose SMYA+INC, and high-dose SMYA+inhibitor groups (n=5). (C) ELISA detected the expression of IL-17A protein in the serum of the rats of the control group, high-dose SMYA, high-dose SMYA+INC, and high-dose SMYA+inhibitor groups (n=5).
[0040] Fig.23This is the effect of miR-548j-5p on the expression of vascular function-related proteins after SMYA treatment in the embodiment of the present invention; Western blot detected the vWF, eNOS and TF proteins in the vascular tissues of the control group, high-dose SMYA group, high-dose SMYA+INC group, and high-dose SMYA+inhibitor group, **p<0.01, (n=5). DETAILED DESCRIPTION
[0041] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0042] It should be noted that the terms used here are only for describing specific embodiments, and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof. If the experimental methods of specific conditions are not indicated in the following specific embodiments, the conventional methods and conditions of molecular biology in the art are usually followed, and such techniques and conditions are fully explained in the literature. See, for example, Sambrook et al., the techniques and conditions described in "Molecular Cloning: Laboratory Manual", or according to the conditions recommended by the manufacturer.
[0043] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out under conventional conditions or under conditions recommended by the sales company; the materials and reagents used in the examples, unless otherwise specified, can be purchased through commercial channels.
[0044] In a typical embodiment of the present invention, a reagent for detecting miR-548j-5p and / or IL-17A is provided for use in preparing a product for screening, (auxiliary) diagnosis, detection, monitoring or prediction of the progression of thromboangiitis obliterans.
[0045] The present invention has found through research that compared with the control group, the expression of IL-17A mRNA in peripheral blood PBMCs of TAO patients is significantly increased, and the expression of miR-548j-5p is significantly decreased. The IL-17A mRNA level in PBMCs is significantly negatively correlated with the expression of miR-548j-5p. Receiver operating characteristic (ROC) analysis shows that miR-548j-5p in PBMCs can sensitively distinguish TAO from the normal control group. Therefore, the reduction of miR-548j-5p may promote the expression of IL-17A in TAO, and therefore it can be used as a biomarker.
[0046] In another specific embodiment of the present invention, a system for screening, (assisting) diagnosing, detecting, monitoring or predicting the progression of thromboangiitis obliterans is provided, the system comprising:
[0047] An acquisition module is configured to: acquire the expression level of miR-548j-5p and / or IL-17A in a sample to be tested of a subject;
[0048] The evaluation module is configured to determine the disease condition of the subject according to the expression level of miR-548j-5p and / or IL-17A obtained by the acquisition module.
[0049] The subject is a human being, which may be a patient with thromboangiitis obliterans or a patient suspected of thromboangiitis obliterans, and the sample to be tested includes but is not limited to peripheral blood (including serum) and peripheral blood mononuclear cells (PBMCs).
[0050] In another specific embodiment of the present invention, there is provided a use of a preparation containing Simiao Yong'an Decoction in at least one of the following:
[0051] (a1) promoting the expression of miR-548j-5p and / or eNOS in vascular endothelial cells or preparing a product that promotes the expression of miR-548j-5p and / or eNOS in endothelial cells;
[0052] (a2) inhibiting the expression of IL-17A, TF and / or vWF in vascular endothelial cells or preparing a product that inhibits the expression of IL-17A, TF and / or vWF in endothelial cells;
[0053] (a3) Drugs for the treatment of thromboangiitis obliterans.
[0054] In another specific embodiment of the present invention, the preparation containing Simiao Yong'an Decoction can be Simiao Yong'an Decoction freeze-dried powder or Simiao Yong'an Decoction drug serum.
[0055] In another specific embodiment of the present invention, the Simiao Yong'an Decoction drug serum is obtained by gavage of Simiao Yong'an Decoction to rats and then sampling blood from the heart.
[0056] In another specific embodiment of the present invention, the raw material composition of the Simiao Yong'an Decoction includes, by weight, 80-100 parts of honeysuckle, 80-100 parts of Scrophularia ningpoensis, 50-70 parts of Angelica sinensis, and 20-40 parts of Licorice.
[0057] In another specific embodiment of the present invention, the raw material composition of the Simiao Yong'an Decoction, calculated by weight, includes: 90 parts of honeysuckle, 90 parts of Scrophularia ningpoensis, 60 parts of Angelica sinensis, and 30 parts of Licorice.
[0058] In another specific embodiment of the present invention, the vascular endothelial cells are specifically human umbilical vein endothelial cells.
[0059] In (a1)-(a2), the product can be a drug or a test reagent. The test reagent can be used for basic scientific experimental research, thereby providing a material basis for research on the occurrence, development and treatment of TAO.
[0060] At the same time, studies have shown that miR-548j-5p can negatively regulate the expression of IL-17A, vWF and TF proteins, promote the expression of eNOS proteins, participate in inflammatory responses, and affect vascular function. Therefore, miR-548j-5p inhibitors (such as miR-548j-5pinhibitor) participate in the formation of TAO and can be used to construct TAO-related cell and animal models. MiR-548j-5p promoters (such as the above-mentioned preparations containing Simiao Yong'an Decoction or miR-548j-5pmimics) can play a therapeutic role in TAO by reducing IL-17A levels.
[0061] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0062] Example
[0063] Experimental methods
[0064] 1. Liquid chromatography-mass spectrometry / mass spectrometry analysis
[0065] LC-MS and MS / MS data were acquired on a UHPLC Ultimate 3000 instrument coupled to a Q-exact Orbitrap-MS spectrometer (Thermo Fisher Scientific, CA, USA). Chromatographic analysis was performed on an ACQUITY UPLCHSS T3 (2.1 × 100 mm, 1.8 m) column. The mobile phase consisted of A (water with 0.05% formic acid) and B (acetonitrile with 0.05% formic acid). The gradient was as follows: 0-2 min, 2% B; 2-30 min, 2%-52% B; 30-32 min, 52%-90% B; 32-32.2 min, 90%-2% B. The column temperature was 30 °C and the flow rate was 0.3 ml / min. The injection volume was 3 μL and the autosampler was kept at a constant temperature of 15 °C. The mass spectrometer was equipped with a HESI source using the following parameters: sheath gas pressure: 45 arb auxiliary gas pressure: 10 arb spray voltage: 3.00 kV; capillary temperature 350 °C; heater temperature 350 °C. Full scan and ddMS2 modes were performed to identify GSLs. The mass range was set from m / z 80 to 1200, negative polarity mode. Possible elemental compositions were obtained by Xcalibur 3.0 (Thermo Fisher Scientific, CA, USA), and only formulas with an error of less than 10 ppm were accepted.
[0066] 2. Collection and processing of clinical samples
[0067] 2.1 Venous blood collection and processing
[0068] The subjects were fasted overnight, and 6 mL of venous blood was collected in the morning. 3 mL was temporarily stored in a tube containing EDTA-Na2 anticoagulant, and 3 mL was temporarily stored in a tube without EDTA-Na2 anticoagulant. The processed samples were coded, serum was separated within 2 hours, and PBMCs were separated.
[0069] 2.2 Collection and processing of peripheral blood serum and PBMCs
[0070] The collected venous blood (without EDTA-Na2 anticoagulant) was centrifuged at 3000 rpm × 10 min, and the supernatant was transferred to an EP tube and stored at -80°C. PBMCs were then collected.
[0071] 2.3 Screening of differentially expressed miRNAs using whole transcriptome gene chips
[0072] 2.3.1 High-throughput detection chip
[0073] Six clinical samples (normal control group, n=3; TAO group, n=3) were detected and analyzed using human miRNA chips at Shanghai Ouyi Biomedical Technology Co., Ltd.
[0074] 2.3.2 Testing process
[0075] The sample RNA was extracted using high-quality reagents, and the sample RNA concentration and RNA integrity were detected using NanoDrop ND-2000 (ThermoScientific) and Agilent Bioanalyzer 2100 (Agilent Technologies), respectively. After passing the quality inspection, the dephosphorylated and denatured RNA was labeled with the fluorescent probe Cyanine-3-CTP (Cy3). The purified labeled RNA was hybridized with the chip, the hybridization signal intensity of the probe molecule was detected, the number and sequence information of the sample molecules were obtained, and finally the original data image was obtained by scanning with Agilent Scanner G2505C (Agilent Technologies).
[0076] 2.3.3 Chip data analysis
[0077] The processed data were used according to the screening criteria of P ≤ 0.05 and fold change (FC ≥ 2), and the differentially expressed miRNAs that met the conditions were retained for subsequent research.
[0078] 2.4 Prediction and screening of potential miRNAs
[0079] 2.4.1 Bioinformatics software prediction
[0080] miRNAs that may bind to IL-17A Bioinformatics software (TargetScan, miRDB) was used to predict miRNAs that may bind to IL-17A.
[0081] 2.4.2 Screening of differential miRNAs that may bind to IL-17A
[0082] Chip detection and bioinformatics software were used to further screen differential miRNAs that may bind to IL-17A.
[0083] 2.5 qRT-PCR detection of IL-17A mRNA expression
[0084] 2.6 qRT-PCR detection of miR-548j-5p expression
[0085] 2.7 qRT-PCR detection of the regulatory effect of miR-548j-5p on IL-17A mRNA expression
[0086] 2.8 ELISA detection of IL-17A protein expression
[0087] 2.9 Immunoblotting
[0088] 2.10 Network pharmacology analysis of Simiaoyong'an decoction
[0089] 2.10.1 Screening of the Active Ingredients and Targets of Simiaoyong'an Decoction
[0090] In the Chinese medicine system pharmacology database and analysis platform, the effective ingredients and targets of Simiao Yong'an Decoction were searched according to oral bioavailability (OB) ≥ 30 and drug likeness (DL) ≥ 0.18. The target names were standardized using the Universal Protein database. 2.10.2 Acquisition of key targets for TAO diseases
[0091] Using "thromboangiitis obliteransr" as the keyword, we searched for TAO-related targets from the comparative toxicogenomics database, and the screening condition was "inference score ≥ 30". Then, the targets of Simiao Yong'an Decoction and TAO disease targets were intersected in the Venn diagram drawing platform Venny 2.1.
[0092] 2.10.3 Drug-disease core target screening and bubble chart drawing
[0093] The STRING database was used to predict the interaction between key proteins, and the cytohhubba plug-in was used for topological analysis. The top ten core targets were screened according to the degree of freedom. On the Metascape data platform, the Kyoto Encyclopedia of Genes and Genomes was used with "P<0.01" as the condition to perform enrichment analysis on the pathways of the core targets and draw bubble charts.
[0094] 2.11 Preparation of Simiao Yong'an Decoction
[0095] Simiaoyong'an Decoction contained 270 g of four herbs, namely 90 g of honeysuckle, 90 g of Scrophularia, 60 g of Angelica, and 30 g of Glycyrrhiza. All the herbs were decocted with distilled water at a ratio of 8:1 (v / w) at 100 °C for 1 h (40 min for the first time; 20 min for the second time), and the extraction was repeated twice. The two decoctions were mixed, filtered, freeze-dried in a freeze dryer (Posen Instrument Co., Ltd., Jinan, China), and concentrated to 66 g. The dried powdered extract was stored at -80 °C before use and dissolved in ddH2O for later use. The herbal materials were collected from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine.
[0096] 2.12 Preparation of drug serum
[0097] To investigate the effect of Simiao Yong'an Decoction on IL-17A / miR-548j-5p in vitro, Wistar rats were randomly divided into four groups: (1) blank group; (2) low-dose group; (3) medium-dose group; and (4) high-dose group. The low-dose group of Simiao Yong'an Decoction was intragastrically administered with 14 g (raw drug) / kg / day, the medium-dose group was intragastrically administered with 28 g (raw drug) / kg / day, and the high-dose group was intragastrically administered with 56 g (raw drug) / kg / day. The intragastrically administered drugs were continuously administered for 7 days. Blood was collected from the heart 2 hours after the last intragastrically administered drug, allowed to stand for 1 hour, and centrifuged at 3000 rpm for 10 minutes to separate the serum. The serum was then inactivated in a 56°C water bath for 30 minutes and filtered with a 0.22 μm sterile microporous membrane. Finally, it was stored at -80°C for future use.
[0098] 2.13TAO model establishment and grouping
[0099] 2.13.1 Animal model establishment
[0100] 8-week-old male Wistar rats weighing about 200 g were used. After fasting for 12 hours before surgery, isoflurane anesthesia was used. The hair was shaved and incised at the midpoint of the groin, and the subcutaneous muscle tissue was peeled off to free the left femoral artery. An artery clamp was used on the proximal segment of the femoral artery to block blood flow. 0.2 ml of a solution containing sodium laurate (5 g / L) was injected below the artery clamp toward the distal end. After completion, a cotton swab was used to press and stop bleeding for 15 minutes, and then suture was performed. Animal experiments were conducted in accordance with the "Guidelines for the Protection and Use of Laboratory Animals" (Shandong University of Traditional Chinese Medicine).
[0101] 2.13.2 Experimental Grouping and Treatment
[0102] Experiment 1: In order to investigate the expression of miR-548j-5p and IL-17A in TAO rats, the rats were randomly divided into control group, sham operation group, TAO group, TAO+Anti-IL-17A group, and TAO+NS group, with 5 rats in each group. The treatment of each group of rats was as follows:
[0103] (1) Control group: The control group did not receive any treatment and was observed on a normal diet for 7 days;
[0104] (2) Sham operation: The left hind limb was shaved at the inguinal femoral artery site and sutured locally. The subjects were observed for 7 days after normal diet.
[0105] (3) TAO group: The rats in the TAO group were treated with sodium laurate to induce vasculitis in the left hind limbs according to the above procedure and then ate a normal diet and observed for 7 days;
[0106] (4) TAO+Anti-IL-17A group: Rats were treated in the same way as (3) and injected with anti-IL-17A antibody (0.1
[0107] mg / kg) for 5 consecutive days;
[0108] (5) TAO+NS group: Rats were treated in the same way as in (3) and injected with an equal volume of normal saline into the tail vein 2 hours after surgery.
[0109] Continue for 5 days;
[0110] After 7 days, the rats were killed by isoflurane and samples (PBMCs, serum and blood vessels) were collected. Some blood vessels / thrombi were stored at -80°C, and some were soaked in fixative for subsequent experiments.
[0111] Experiment 2: In vivo observation of the effect of regulating the expression of Simiao Yong'an Tang on the occurrence of IL-17A / miR-548j-5p. Wistar rats were randomly divided into 4 groups, with 5 rats in each group: 1) control group; (2) sham operation group; (3) TAO group; (4) TAO + Simiao Yong'an Tang low-dose group; (5) TAO + Simiao Yong'an Tang medium-dose group; (6) TAO + Simiao Yong'an Tang high-dose group. The clinical effective dose of TAO for humans is 270g / 60kg. Based on the equivalent conversion of animal and human surface areas and on the basis of the recommended dose. The low-dose TAO group was gavaged with 14g (raw drug) / kg / day, the medium-dose group was gavaged with 28g (raw drug) / kg / day, and the high-dose group was gavaged with 56g (raw drug) / kg / day. Each group of rats was gavaged for 7 consecutive days. Vascular Doppler ultrasound examination was performed 2 hours after the last intragastric administration. After the rats were euthanized, fresh thrombi were obtained and their length and weight were measured.
[0112] Experiment 3: In order to observe the changes of the effect of Simiao Yong'an Decoction on IL-17A / miR-548j-5p after injection of miR-548j-5p inhibitor in vivo, Wistar rats were randomly divided into 4 groups, 5 rats in each group, and the treatments were as follows:
[0113] (1) TAO+PBS group: 200 μl of PBS was injected into the tail vein after 7 days of normal diet;
[0114] (2) TAO (high dose) + PBS group: 56 g (raw drug) / kg / day was administered by intragastric gavage for 7 days. 200 μl of PBS was injected into the tail vein 2 hours after the last intragastric gavage;
[0115] (3) TAO (high dose) + miR-548j-5p inhibitor group: 56 g (raw drug) / kg / day was administered by intragastric administration for 7 days. 2 hours after the last intragastric administration, 200 μl of PBS containing 45 nmol miR-548j-5p inhibitor was injected into the tail vein;
[0116] (4) TAO (high dose) + miR-548j-5p INC group: 56 g (raw drug) / kg / day was administered by intragastric gavage for 7 days. 2 hours after the last intragastric gavage, 200 μl of PBS containing 45 nmol miR-548j-5p INC was injected into the tail vein.
[0117] After 48 h, samples (PBMCs, serum and blood vessels) were collected. Some blood vessels / thrombi were stored at -80°C, and some were soaked in fixative for subsequent experiments.
[0118] 2.14 Doppler color ultrasound detection of thrombosis in rats
[0119] 2.15 Weighing and measuring rat thrombus
[0120] After blood was collected from the rat heart, the rat was fixed and opened along the original surgical incision to observe the thrombosis formation in the femoral artery, and the femoral artery thrombus was taken to measure its length and weight.
[0121] 2.16HE staining to detect thrombosis in rats
[0122] Experimental Results
[0123] 1Analysis of the chemical components of Simiao Yong'an Decoction by LC-MS / MS
[0124] To evaluate the main chemical components, we used liquid chromatography-mass spectrometry / mass spectrometry (LC-MS / MS) in positive and negative ion modes to analyze Simiao Yongan decoction ( Figure 1 ). The results showed that it contained characteristic chemicals of Simiao Yong'an Decoction, such as luteolin, zp-luteolin and glycine.
[0125] 2. IL-17A expression is upregulated in TAO patients
[0126] IL-17A is an important inflammatory factor involved in the occurrence of multiple arterial vascular diseases. To explore whether IL-17A is involved in the occurrence of TAO, we first performed qRT-PCR and ELISA tests. qRT-PCR detection found that the expression of IL-17A mRNA in PBMCs of TAO patients was significantly increased compared with the control group (P<0.05) ( Figure 2 A). ELISA results showed that the expression of IL-17A protein in the serum of TAO patients was significantly increased compared with that in the control group (P<0.05) ( Figure 2 B), suggesting that IL-17A is involved in the occurrence of TAO.
[0127] 3. Prediction and screening of differential miRNAs regulating IL-17A by miRNA gene chip and software
[0128] To explore the abnormal miRNAs in PBMCs of TAO patients, the miRNA expression profiles in PBMCs of 3 TAO patients and 3 normal subjects were analyzed using miRNA chip technology. Since the occurrence of TAO is related to IL-17A, we used bioinformatics software Chip, TargetScan and miRDB to screen potential miRNAs, among which miR-548j-5p may have a potential binding site with IL-17A mRNA 3'UTR ( Figure 3 ). This suggests that miR-548j-5p may interact with IL-17A and participate in the occurrence of TAO.
[0129] The expression of miR-548j-5p in chip samples and PBMCs of 40 clinical samples (20 in the control group and 20 in the TAO group) was detected by qRT-PCR. The results showed that the gene expression of miR-548j-5p in TAO patients was significantly decreased compared with that in the normal control group, and the difference was statistically significant (P<0.05). The results are shown in ( Figure 4 A, B). In order to study the relationship between miR-548j-5p and IL-17A, we used Pearson correlation analysis to explore the correlation between the two. The results showed that the IL-17A mRNA level in PBMCs was significantly negatively correlated with the expression of miR-548j-5p. The results are shown in ( Figure 4 C). Receiver operating characteristic (ROC) analysis showed that miR-548j-5p in PBMCs could sensitively distinguish TAO from normal control group ( Figure 4 D), with an area under the curve of 0.9075 (95% confidence interval: 0.8146 to 1.000). These data suggest that the reduction of miR-548j-5p may promote the expression of IL-17A in TAO and encourage us to further verify the role of miR-548j-5p and IL-17A in TAO formation.
[0130] 4miR-548j-5p negatively regulates the expression of IL-17A
[0131] In order to explore the relationship between miR-548j-5p and IL-17A, we transfected miR-548j-5p mimics and inhibitors in HUVECs to regulate the expression of miR-548j-5p and observe the effect on IL-17A. The results showed that the expression of miR-548j-5p was significantly increased after transfection with miR-548j-5p mimics, and the expression was significantly decreased after transfection with miR-548j-5p inhibitor (P<0.05), as shown in Figure (5A, B). At the same time, upregulating miR-548j-5p expression can significantly reduce the expression of IL-17A mRNA, and downregulating miR-548j-5p expression can significantly increase the expression of IL-17A mRNA (P<0.05), as shown in Figure (5C, D). This suggests that miR-548j-5p can negatively regulate IL-17A mRNA expression. After HUVECs were transfected with miR-548j-5p mimics, the expression of IL-17A, vWF and TF proteins was significantly decreased, and the expression of eNOS protein was significantly increased (P<0.05); after transfection with miR-548j-5 inhibitor, the expression of IL-17A, vWF and TF proteins was significantly increased, and the expression of eNOS protein was significantly decreased (P<0.05), indicating that miR-548j-5p can negatively regulate the expression of IL-17A, vWF and TF proteins, promote the expression of eNOS protein, participate in inflammatory response, and affect vascular function. The results are shown in ( Figure 6 , 7).
[0132] IL-17A is a direct target gene of miR-548j-5p
[0133] In order to clarify the targeted regulatory relationship of miR-548j-5p on IL-17A, TargetScan was used to predict the binding sites. The results showed that there were two potential binding sites between miR-548j-5p and IL-17A mRNA 3'UTR. The results are shown in ( Figure 8 A). miR-548j-5p mimics could significantly reduce the relative luciferase activity of WT-pmirGLO-IL-17A3'UTR, Mut1-pmirGLO-IL-17A 3'UTR and Mut2-pmirGLO-IL-17A 3'UTR (P<0.05), but did not affect the relative luciferase activity of Mut1+2-pmirGLO-IL-17A3'UTR (P>0.05). The results are shown in ( Figure 8 B). The above results confirmed that miR-548j-5p directly binds to IL-17A mRNA through base complementarity, thereby inhibiting the expression of IL-17A.
[0134] 6miR-548j-5p and IL-17A are involved in the formation of TAO rats
[0135] 6.1 Establishment of TAO rat model
[0136] To conduct in vivo animal experiments, we established a TAO rat model, observed for 7 days, and then killed the rats with isoflurane to collect blood vessel or thrombus samples for analysis. HE and Doppler ultrasound showed that 100% (n=5) of the TAO rat models had thrombi, while no thrombi were formed in the control group and the sham operation group, which confirmed that the model was successful ( Fig. 9 A, B).
[0137] 6.2 Reduced expression of miR-548j-5p and increased expression of IL-17A are involved in the formation of TAO
[0138] qRT-PCR detection showed that the expression of miR-548j-5p in PBMCs of TAO rats was significantly lower than that in PBMCs of normal control group and sham operation group rats ( Fig.10 A). At the same time, the expression of IL-17A in PBMCs increased significantly ( Fig.10 B, C). In addition, we used Western Blot experiments to detect the regulatory effect of miR-548j-5p on vascular-related proteins. Compared with normal control and sham-operated rats, the protein expressions of TF and vWF in vascular tissues of TAO rats were significantly increased, while the expression of eNOS protein was significantly decreased ( Fig.11 ).
[0139] 6.3 Reduced IL-17A expression is involved in the formation of TAO
[0140] To determine whether IL-17A is the pathogenic factor of TAO, we injected IL-17A antagonists into TAO rats to neutralize the function of IL-17A. HE detection showed that the thrombus area in the Anti-IL-17A group was reduced compared with the control group ( Fig.12 ), which indicates that IL-17A is an important risk factor for the formation of TAO.
[0141] 7Si Miao Yong An Tang regulates miR-548j-5p / IL-17A in vitro to participate in the treatment of TAO
[0142] 7.1 Network pharmacology prediction of the therapeutic effect of Simiaoyong'an decoction on TAO
[0143] In order to study the mechanism of action of Simiao Yong'an Decoction on TAO, 201 key targets of Simiao Yong'an Decoction against TAO were screened using network pharmacology. According to the screening conditions, KEGG pathway enrichment analysis was performed with p<0.01, and 208 pathways were obtained, including the IL-17 signaling pathway ( Fig.13 ).
[0144] 7.2 Simiao Yong'an Decoction positively regulates miR-548j-5p to inhibit IL-17A and affect vascular function
[0145] To clarify the effect of Simiao Yong'an Decoction on miR-548j-5p and IL-17A, HUVECs were cultured in vitro for 24 h using serum from the control group and 5%, 10%, and 20% drug-containing serum. qRT-PCR detection showed that the expression of miR-548j-5pmRNA increased with the increase of drug concentration compared with the control group ( Fig.14 A), while IL-17A mRNA ( Fig.14 B) decreased with the increase of drug-containing serum concentration. In addition, ELISA test results showed that IL-17A protein ( Fig.14 C) also showed a downward trend with the increase of serum drug concentration. In addition, the expression of vWF and TF proteins in HUVECs decreased gradually, while the expression of eNOS protein increased gradually ( Fig.15 ). 7.3 miR-548j-5p inhibitor reverses the effect of Simiao Yong'an decoction serum in vitro
[0146] To further confirm the pathogenic role of miR-548j-5p in the formation and development of TAO, we transfected miR-548j-5p inhibitor into HUVECs cultured with 20% drug-containing serum to inhibit the expression of miR-548j-5p. The experimental results showed that the expression of miR-548j-5p in the inhibitor group was significantly lower than that in the INC group ( Fig.16 A), and IL-17A mRNA ( Fig.16 B) and protein ( Fig.16 C) showed the opposite expression trend. At the same time, the inhibitory effect on vWF and TF and the promoting effect on eNOS were significantly weakened after using miR-548j-5p inhibitor ( Fig.17 ). This indicates that Simiao Yong'an Decoction regulates IL-17A through miR-548j-5p, thereby affecting the expression of vascular-related proteins.
[0147] 8 Simiao Yong'an Decoction regulates miR-548j-5p / IL-17A in vivo to participate in the treatment of TAO
[0148] 8.1 Effect of Simiaoyong'an Decoction on Thrombosis in Rats
[0149] We administered Simiao Yong'an decoction to TAO rats by gavage to further explore the mechanism of action of Simiao Yong'an decoction in TAO. Compared with the TAO group, Doppler ultrasound showed that the thrombus gradually decreased in the low-dose Simiao Yong'an decoction, medium-dose Simiao Yong'an decoction, and high-dose Simiao Yong'an decoction treatment groups ( Fig.18 A). In addition, the weight and length of thrombi in the treatment group decreased with increasing concentrations ( Fig.18 B).
[0150] 8.2 Simiao Yong'an Decoction upregulates miR-548j-5p in vivo and plays a therapeutic role in TAO by reducing IL-17A levels
[0151] In qRT-PCR detection, the expression of miR-548j-5p mRNA in the low-dose Simiao Yong'an Tang, medium-dose Simiao Yong'an Tang and high-dose Simiao Yong'an Tang treatment groups was increased compared with the control group ( Fig.19 A). However, the expression of IL-17A in qRT-PCR and ELISA tests showed a gradual decrease ( Fig.19 B, C). Compared with the vascular tissues of rats in the TAO group, Western blot results showed that the expression of vWF and TF proteins in the vascular tissues of the treatment group gradually decreased, while the expression of eNOS protein gradually increased with the increase of drug concentration ( Fig. 20 ).
[0152] 8.3 Effect of reducing miR-548j-5p expression on thrombosis in rats
[0153] To further verify the role of miR-548j-5p in the treatment of TAO in vivo, we injected miR-548j-5p inhibitor into TAO rats to inhibit the expression of miR-548j-5p. The experiment showed that the miR-548j-5p inhibitor group still had significant thrombosis compared with the high-dose Simiao Yong'an Decoction + INC group ( Fig.21 ).
[0154] 8.4 Inhibition of miR-548j-5p can reverse the therapeutic effect of Simiaoyongan decoction in vivo
[0155] In the qRT-PCR experiment, the mRNA level of miR-548j-5p in the vascular tissue of the high-dose Simiao Yong'an Tang group was significantly increased compared with the TAO group. However, the efficacy of Simiao Yong'an Tang was blocked by the injection of miR-548j-5p inhibitor ( Fig. 22 A). The protein and mRNA levels of IL-17A in the serum of the high-dose Simiao Yong'an Tang group were also significantly reduced, but after the injection of miR-548j-5p inhibitor, the inhibitory effect of Simiao Yong'an Tang on IL-17A was weakened ( Fig. 22 B, C). At the same time, after injection of miR-548j-5p inhibitor, the expression of vWF, TF and eNOS proteins was also affected, which is consistent with the results of in vitro experiments ( Fig.23 ).
[0156] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of a reagent for detecting miR-548j-5p in the preparation of a product for diagnosing the progression of thromboangiitis obliterans; The sample to be tested includes peripheral blood mononuclear cells.
2. A system for diagnosing the progression of thromboangiitis obliterans, characterized in that: The system comprises: An acquisition module is configured to: acquire the expression level of miR-548j-5p in a sample to be tested of a subject; An evaluation module, configured to: determine the disease condition of the subject according to the expression level of miR-548j-5p obtained by the acquisition module; The sample to be tested includes peripheral blood mononuclear cells.
3. The system according to claim 2, characterized in that: The subject is a human.
